3D Systems launches commercial denture printing solution in US market

ROCK HILL, S.C. - 3D Systems (NYSE:DDD), a $243 million market cap company currently rated as undervalued according to InvestingPro analysis, announced Tuesday the full commercial release of its NextDent Jetted Denture Solution for the U.S. market, a new technology for producing single-piece, multi-material dentures.

The solution centers around the NextDent 300 MultiJet 3D printer, which produces fully cured dentures without requiring additional post-curing steps. The system uses two FDA-cleared materials - NextDent Jet Teeth and NextDent Jet Base - to create prosthetics that combine tooth rigidity with gum support. This innovation comes as the company faces challenging market conditions, with InvestingPro data showing an 8% revenue decline in the last twelve months.

According to the company, the technology enables dental labs to produce dentures with up to 50% less manual labor compared to traditional methods. The digital workflow can deliver a final product in one day versus the typical five-day turnaround for conventional production.

"Our monolithic jetted denture solution is a truly unique market offering, fusing innovative materials, 3D printing technology, software, and applications expertise," said Stijn Hanssen, director of dental solutions at 3D Systems.

Following beta testing with select U.S. dental labs, 3D Systems is now taking orders for the NextDent 300 printer, with initial shipments planned for August 2025. European and Asian releases will follow pending regulatory approvals.

The company estimates that applications for dental "replacement" in the United States represent an approximately $600 million addressable market by 2029, about one-third of the total global opportunity. While the market potential is significant, InvestingPro analysis indicates the company faces near-term challenges with cash burn and profitability. For deeper insights into 3D Systems’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

The NextDent Jetted Denture Solution joins 3D Systems’ portfolio of dental applications that address straightening, protecting, repairing, and replacing teeth.

This article is based on a press release statement from 3D Systems.

In other recent news, 3D Systems reported disappointing financial results for the first quarter of 2025, with earnings per share at -$0.28, which was below the expected -$0.14. The company’s revenue also fell short of projections, totaling $94.5 million compared to the anticipated $100.34 million. In a strategic move, 3D Systems completed financial transactions to retire approximately $88 million of its debt, representing 41% of its previous balance. The company issued $92 million in convertible senior secured notes due 2030, with the proceeds aimed at repurchasing a portion of its outstanding debt. Additionally, 3D Systems announced FDA approval for its 3D-printed bioabsorbable nerve repair device, developed in collaboration with French MedTech company TISSIUM. Craig-Hallum analyst Greg Palm recently reduced the price target for 3D Systems to $2.00 from $2.50, maintaining a Hold rating due to weaker-than-expected results. The analyst noted decreased activity in consumables and printers and highlighted the company’s focus on returning to profitability with planned cost reductions. These developments reflect 3D Systems’ ongoing efforts to address financial challenges and innovate in the medical technology field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.